pages:
-
A Patient-Centered Approach for Addressing Access to Care to Improve Outcomes in Heart Failure Patients
Research Grant
-
A patient-centered approach to address racial/ethnic disparities in pathways to dementia diagnosis
Fellowships, Supported Research, and Other Grants
-
A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care
Research Grant
-
A performance evaluation of the nanomix eLab Troponin I Assay with the nanomix elab System
-
A Persistent Rna-Dna Hybrid At A T4 Replication Origin
-
A Personalized Metabolomic Approach to Human Obesity and Weight Loss
Research Grant
-
A Ph. 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & ER Formulation (DELEXIS) of Methylphenidate Hydrochloride, on Post waking, Early Mor
-
A Ph.3,Multicenter,Randomized,Doubleblind,Placebo-controlledStudy with anOpenlabelPhase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in LevodopaTreated patients with Parkinson's disease ExperiencingEndofdose "Wearing Off"
-
A Ph3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety/Efficacy Study of a Fluocinolone Acetonide Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Research Grant
-
A Pharmacokinetic Study of Aptensio XR¿ (Methylphenidate Hydrochloride) Extended-Release capsules in Male or Female Pre-School Children 4 to Under 6 years of age with ADHD in Fed Condition
-
A Phase 0 Study to Preliminarily Assess the Janssen Autism Knowledge Engine in Children and Adults with ASD
-
A phase 1 / 2 multicenter study of BMS-986012 in subjects with relapsed/refractory small cell lung cancer.
-
A phase 1 / 2 randomized, blinded, placebo controlled study of Ipilimumab in combination with INCB024360 or placebo in unresectable or metastatic melanoma
-
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination with Capecitabine Tablets in Patients with HER2-Positive Advanced Solid Tumors
-
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of
Anti-CD19 Allogeneic CRISPR-Cas9?Engineered T Cells (CTX110) in Subjects With
Relapsed or Refractory B Cell Malignancies
-
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
-
A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
-
A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Glioma
-
A phase 1 first in human open labe dose escalation study of MGD007 a humanized gpA33 x CD3 dual affinity retargeted (DART) protein i patients with relapsed refractory metastatic colorectal carcinoma
-
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
-
A Phase 1 multicenter, open label study of enadenotucirev combined with PD-1 inhibitor in subjects with metastatic or advanced epithelial tumors
-
A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors
-
A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects with Early Parkinson's Disease
-
A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB 7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren¿s
-
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity ofABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR) or its Ligands
-
A Phase 1 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3b) inhibitor
-
A Phase 1 Study of AAV8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
-
A Phase 1 Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects
with Relapsed or Refractory Small Cell Lung Cancer
-
A PHASE 1 STUDY OF DS-3032B IN COMBINATION
WITH QUIZARTINIB IN SUBJECTS WITH
FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA
THAT ARE RELAPSED/REFRACTORY, OR
NEWLY DIAGNOSED AND UNFIT FOR INTENSIVE
CHEMOTHERAPY
-
A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)
pages: